WBH Advisory Inc. Invests $212,000 in Stryker Corporation $SYK

WBH Advisory Inc. bought a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 537 shares of the medical technology company’s stock, valued at approximately $212,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of SYK. Nuveen LLC acquired a new stake in shares of Stryker during the first quarter worth $558,075,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after buying an additional 549,643 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.3%

SYK stock opened at $379.96 on Wednesday. The company has a market cap of $145.26 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.75 and a beta of 0.94. The business has a 50-day simple moving average of $379.56 and a 200 day simple moving average of $379.10. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is presently 44.50%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Evercore ISI dropped their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Wells Fargo & Company lifted their target price on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday. UBS Group set a $408.00 price target on Stryker in a research note on Monday, October 13th. Finally, BTIG Research boosted their price target on Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $431.76.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.